Trial Profile
Phase I/II Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs CD154 gene therapy (Primary) ; Pembrolizumab
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 21 Nov 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 28 Sep 2017 Planned primary completion date changed from 1 Dec 2020 to 1 Mar 2022.
- 28 Sep 2017 Planned initiation date changed from 1 Dec 2016 to 1 Mar 2018.